Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 98.65
MED's Cash-to-Debt is ranked higher than
75% of the 928 Companies
in the Global Specialty Retail industry.

( Industry Median: 0.97 vs. MED: 98.65 )
Ranked among companies with meaningful Cash-to-Debt only.
MED' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.81 Max: 306.43
Current: 98.65
0.1
306.43
Equity-to-Asset 0.79
MED's Equity-to-Asset is ranked higher than
90% of the 913 Companies
in the Global Specialty Retail industry.

( Industry Median: 0.49 vs. MED: 0.79 )
Ranked among companies with meaningful Equity-to-Asset only.
MED' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.72 Max: 0.79
Current: 0.79
-0.1
0.79
Interest Coverage N/A
MED's Interest Coverage is ranked higher than
86% of the 784 Companies
in the Global Specialty Retail industry.

( Industry Median: 25.75 vs. MED: N/A )
Ranked among companies with meaningful Interest Coverage only.
MED' s Interest Coverage Range Over the Past 10 Years
Min: 14.77  Med: 5142.03 Max: No Debt
Current: N/A
Piotroski F-Score: 7
Altman Z-Score: 17.44
Beneish M-Score: -3.05
WACC vs ROIC
5.27%
104.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 9.78
MED's Operating Margin % is ranked higher than
79% of the 924 Companies
in the Global Specialty Retail industry.

( Industry Median: 3.40 vs. MED: 9.78 )
Ranked among companies with meaningful Operating Margin % only.
MED' s Operating Margin % Range Over the Past 10 Years
Min: 6.52  Med: 9.6 Max: 12.28
Current: 9.78
6.52
12.28
Net Margin % 6.50
MED's Net Margin % is ranked higher than
79% of the 924 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.06 vs. MED: 6.50 )
Ranked among companies with meaningful Net Margin % only.
MED' s Net Margin % Range Over the Past 10 Years
Min: 4.45  Med: 6.36 Max: 7.61
Current: 6.5
4.45
7.61
ROE % 19.36
MED's ROE % is ranked higher than
83% of the 906 Companies
in the Global Specialty Retail industry.

( Industry Median: 6.04 vs. MED: 19.36 )
Ranked among companies with meaningful ROE % only.
MED' s ROE % Range Over the Past 10 Years
Min: 12.72  Med: 21.54 Max: 32.27
Current: 19.36
12.72
32.27
ROA % 14.91
MED's ROA % is ranked higher than
92% of the 931 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.74 vs. MED: 14.91 )
Ranked among companies with meaningful ROA % only.
MED' s ROA % Range Over the Past 10 Years
Min: 9.54  Med: 16.16 Max: 25.01
Current: 14.91
9.54
25.01
ROC (Joel Greenblatt) % 115.67
MED's ROC (Joel Greenblatt) % is ranked higher than
94% of the 928 Companies
in the Global Specialty Retail industry.

( Industry Median: 12.00 vs. MED: 115.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MED' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.47  Med: 69.8 Max: 110.06
Current: 115.67
24.47
110.06
3-Year Revenue Growth Rate -3.80
MED's 3-Year Revenue Growth Rate is ranked lower than
61% of the 775 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.20 vs. MED: -3.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MED' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -45.9  Med: 28.7 Max: 63.7
Current: -3.8
-45.9
63.7
3-Year EBITDA Growth Rate -6.00
MED's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 655 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.90 vs. MED: -6.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MED' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6  Med: 24.2 Max: 78.5
Current: -6
-6
78.5
3-Year EPS without NRI Growth Rate -8.70
MED's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 591 Companies
in the Global Specialty Retail industry.

( Industry Median: 1.70 vs. MED: -8.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MED' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -14.1  Med: 20.85 Max: 68.9
Current: -8.7
-14.1
68.9
GuruFocus has detected 4 Warning Signs with Medifast Inc $MED.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MED's 10-Y Financials

Financials (Next Earnings Date: 2017-06-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MED Guru Trades in Q1 2016

Paul Tudor Jones 16,900 sh (New)
Jim Simons 827,900 sh (+10.93%)
Barrow, Hanley, Mewhinney & Strauss 70,347 sh (-22.17%)
» More
Q2 2016

MED Guru Trades in Q2 2016

Paul Tudor Jones 25,100 sh (+48.52%)
Jim Simons 953,600 sh (+15.18%)
Barrow, Hanley, Mewhinney & Strauss 70,329 sh (-0.03%)
» More
Q3 2016

MED Guru Trades in Q3 2016

Barrow, Hanley, Mewhinney & Strauss Sold Out
Jim Simons 947,200 sh (-0.67%)
Paul Tudor Jones 5,722 sh (-77.20%)
» More
Q4 2016

MED Guru Trades in Q4 2016

Paul Tudor Jones 9,300 sh (+62.53%)
Jim Simons 951,500 sh (+0.45%)
» More
» Details

Insider Trades

Latest Guru Trades with MED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Apparel & Specialty » Specialty Retail    NAICS: 445299    SIC: 2099
Compare:NYSE:JMEI, NAS:FTD, NYSE:HZO, NAS:FINL, NYSE:VSI, NAS:WINA, NYSE:PIR, NAS:ZUMZ, NYSE:XOXO, NYSE:BNED, NAS:OSTK, NAS:HIBB, NYSE:SYX, NYSE:NETS, NAS:FLWS, NYSE:BKS, NAS:LE, NAS:PCMI, NAS:BGFV, OTCPK:IDGBF » details
Traded in other countries:MDF.Germany,
Headquarter Location:USA
Medifast Inc is engaged in the productions, distributions, and sales of weight loss and weight management products and other consumable health and diet products. Its products line include weight loss and management, meal replacement, and vitamins.

Medifast Inc is a Delaware Corporation, incorporated in 1993. The Company is engaged in the productions, distributions, and sales of weight loss and weight management products and other consumable health and diet products. Its product lines include weight loss and management, meal replacement, and vitamins. Its products and services are sold to weight loss program participants via the Internet, telephone, and brick and mortar clinics. It operates in two reportable segments; Medifast, and MWCC and Wholesale. The Medifast segment consists of the sales from Medifast Direct Marketing and Take Shape For Life. The MWCC and Wholesale segment consists of the sales of Medifast Corporate and Franchise Weight Control Centers as well as Medifast Wholesale Physicians and international sales. Medifast Weight Control Centers is the brick and mortar clinic channel of the Company with affiliate-owned locations in Pennsylvania, New Jersey, Delaware, Texas, Florida, Maryland, North Carolina and Virginia. Medifast Weight Control Centers offer a high-touch model including comprehensive Companys programs for weight loss and maintenance, customized client counseling, an InBody body composition analysis, and monitoring with a BodyGem indirect calorimeter that determines resting metabolic rates. In the direct-to-consumer channel, Medifast Direct, customers order its product directly through the Companys website, www.medifast1.com or its in-house call center. Take Shape For Life is the personal coaching division of the Company. It enriches lives by providing clinically proven weight loss and weight management products and programs. It offers clinically proven products and programs for weight management, weight maintenance, and long-term health through multiple channels of distribution. It offers a variety of weight loss and weight management products under the Medifast and Essential 1 brands and for select private label customers. Its line includes more than 75 options, including, but not limited to bars, bites, pretzels, puffs, cereal crunch, drinks, eggs, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The Company continues to build and leverage its core brand through multiple marketing strategies for each of its distinct distribution channels such as Medifast Direct, Medical Wholesale, Medifast Weight Control Centers, and Take Shape For Life to their target audiences. It has also developed a comprehensive social media utilizing Facebook, Twitter, YouTube, blogger endorsements, and more. The Company competes with NutriSystem Inc., Herbalife Ltd., USANA Health Sciences, and Weight Watchers International, Inc. The formulation, processing, packaging, and labeling of the Company's products is subject to regulation by several federal agencies, but principally by the FDA.

Top Ranked Articles about Medifast Inc

Medgold Is Granted a Drilling Permit at the Boticas Gold Project, Portugal

VANCOUVER, CANADA--(Marketwired - Jul 6, 2016) - Medgold Resources Corp. (TSX VENTURE:MED) (the "Company" or "Medgold") is pleased to announce that it has received formal approval for the proposed diamond drilling program at the Limarinho Zone at the Boticas Gold Project. Medgold is planning a 2,500m diamond drilling program, expected to commence in mid-July, targeting a gold-bearing sheeted orogenic vein system. Energold Drilling Corp. have been selected as drill contractors to complete the initial drilling program using man-portable drill rigs. Dan James, President of Medgold, said: "We are very pleased to have received formal approval of the Centerra-funded drill program at the Limarinho Zone. With the permit in hand, we can now start a detailed evaluation of the main prospect, Limarinho. Our aims are to confirm the historical drill intercepts and to define a mineral resource over the area. In February last year, the Portuguese government classified Boticas as a Project of Strategic National Interest, which highlights the importance of the project to Portugal." The exploration work at the Boticas Gold Project is fully-funded by our joint venture partner, Centerra Gold Inc. The JV with Centerra started in December 2015, and since that time, Medgold has undertaken grid-soil sampling over Limarinho and the wider region, and has completed a number of phases of channel-chip sampling. The Boticas-Chaves Gold Project The Boticas-Chaves Gold Project is comprised of two exploration licences covering a total area of approximately 600 sq km located in the north of Portugal close to the Spanish border. The principal prospect at Boticas is the Limarinho zone. In the 1980s and 2000s COGEMA and then Kernow Resources, respectively, completed over 3,000m of diamond drilling at Limarinho. The drilling cut broad zones of low-grade gold mineralization (approx. 1 g/t Au), and also multiple mineralized corridors of higher grade (2-3 g/t Au) that are continuous over significant strike lengths. Medgold recently completed a re-evaluation of the historical drilling data, applying strict compositing criteria of a 0.2 g/t Au cut-off and a maximum of 3m internal dilution. The re-calculated drill intersections are summarized below 1:

PFR17: 15.60m @ 3.25 g/t Au from 70.95m
KL04: 38.40m @ 1.96 g/t Au from 19.30m
KL04: 9.00m @ 3.59 g/t Au from 143.30m
KL03: 15.80m @ 2.14 g/t Au from 9.85m
PFR3: 29.60m @ 1.88 g/t Au from 28.20m
PFR10: 56.60m @ 1.33 g/t Au from 72.80m
PFR11: 25.50m @ 1.62 g/t Au from 51.10m



1These are historical data provided for information purposes, and a Qualified Person has not completed the work necessary to verify these results. The mineralized corridors trend east-northeast, while the veins within them trend northeast. The mineralization is structurally controlled and developed within a large deformational zone which coincides with the surface soil geochemistry, outlining a northeast-elongate area of approximately 4km by 2km. This anomaly covers both Limarinho and Limarinho South, both of which are located in the centre of the deformation zone About Centerra Gold and the Joint Venture Centerra is a Canadian-based gold mining company focused on operating, developing, exploring and acquiring gold properties primarily in Asia, North America and other markets worldwide. Centerra is the largest Western-based gold producer in Central Asia. Centerra's shares trade on the Toronto Stock Exchange (TSX) under the symbol CG. The Company is headquartered in Toronto, Ontario, Canada. Centerra has the exclusive right to earn a 51% interest in the Valongo Belt properties (namely: Lagares, Castelo de Paiva and Valongo licences) and the Boticas-Chaves Project by incurring expenditures on the properties totaling US$3.0 million over three years. Once Centerra has acquired the initial 51% interest in the properties, it may acquire a further 19% (for a total 70% interest) by incurring an additional US$3.0 million on exploration within two years. Qualified Person David Clark, PGeo, consulting geologist to the Company, is a Qualified Person as defined by National Instrument 43-101 -- Standards of Disclosure for Mineral Projects. Mr. Clark has reviewed and approved the disclosure of technical information contained in this news release. About Medgold Medgold is a European-focused, TSX-V listed exploration and development company targeting gold properties in northwest Iberia and the under-explored gold provinces of southern Europe. Run by a highly experienced management team with a successful track record of building value in resource companies, Medgold is aiming to become a leading European gold company. Additional information on Medgold can be found on the Company's website at www.medgoldresources.com and by reviewing the Company's page on SEDAR at www.sedar.com. ON BEHALF OF THE BOARD Daniel P. James, President & Director Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. Forward-looking statements Certain statements contained in this news release constitute forward-looking statements within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, are forward-looking statements and include, without limitation, statements about the proposed drill program on the Boticas Gold Project. Often, but not always, these forward looking statements can be identified by the use of words such as "estimate", "estimates", "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "upgraded", "offset", "limited", "contained", "reflecting", "containing", "remaining", "to be", "periodically", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by forward-looking statements. Such uncertainties and factors include, among others, whether the proposed drill program on the Boticas Gold Project will proceed as planned; changes in general economic conditions and financial markets; the Company or any joint venture partner not having the financial ability to meet its exploration and development goals; risks associated with the results of exploration and development activities, estimation of mineral resources and the geology, grade and continuity of mineral deposits; unanticipated costs and expenses; and such other risks detailed from time to time in the Company's quarterly and annual filings with securities regulators and available under the Company's profile on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to: that the proposed drill program on the Boticas Gold Project will proceed as planned; that the Company's stated goals and planned exploration and development activities will be achieved; that there will be no material adverse change affecting the Company or its properties; and such other assumptions as set out herein. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on forward-looking statements.






President
Dan James (UK)
[email protected]
44 7972 579188




Read more...
Medgold Grants Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 29, 2016) - Medgold Resources Corp. (TSX VENTURE:MED) announces that it has granted incentive stock options to its directors, officers, employees and consultants to purchase up to a total of 2,580,000 shares of Medgold exercisable for ten years at a price of $0.15 per share. About Medgold Medgold is a European-focused, TSX-V listed exploration and development company targeting gold properties in northwest Iberia and the under-explored gold provinces of southern Europe. Run by a highly experienced management team with a successful track record of building value in resource companies, Medgold is aiming to become a leading European gold company. Additional information on Medgold can be found on the Company's website at www.medgoldresources.com and by reviewing the Company's page on SEDAR at www.sedar.com. ON BEHALF OF THE BOARD Simon Ridgway, Chief Executive Officer Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. Forward-looking statements Certain statements contained in this news release constitute forward-looking statements within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, are forward-looking statements and include, without limitation, statements about the intended issuance of shares for services. Often, but not always, these forward looking statements can be identified by the use of words such as "estimate", "estimates", "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "upgraded", "offset", "limited", "contained", "reflecting", "containing", "remaining", "to be", "periodically", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by forward-looking statements. Such uncertainties and factors include, among others, whether the Company will issue the shares for services as planned; changes in general economic conditions and financial markets; the Company or any joint venture partner not having the financial ability to meet its exploration and development goals; risks associated with the results of exploration and development activities, estimation of mineral resources and the geology, grade and continuity of mineral deposits; unanticipated costs and expenses; and such other risks detailed from time to time in the Company's quarterly and annual filings with securities regulators and available under the Company's profile on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to: that the Company will issue the shares for services as planned; that the Company's stated goals and planned exploration and development activities will be achieved; that there will be no material adverse change affecting the Company or its properties; and such other assumptions as set out herein. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on forward-looking statements.





Medgold Resources Corp.
Dan James (UK)
President
[email protected]
44 7972 579188




Read more...
Medgold Completes Private Placement to Fortuna Silver Mines

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 21, 2016) - Medgold Resources Corp. (TSX VENTURE:MED) is pleased to advise that it has closed its previously announced non-brokered private placement financing with the issuance to Fortuna Silver Mines Inc. of 10.0 million units at $0.15 per unit, for proceeds of $1.5 million. Each unit consists of one common share of Medgold and one warrant entitling Fortuna to purchase one additional common share of Medgold at $0.15 for one year from closing. The common shares and warrants issued are subject to a resale restriction until October 18, 2016. No finder's fees or commissions were paid in connection with this financing. The proceeds of the placement will be used to fund project-generating exploration in Serbia, and for general working capital purposes. Dan James, President of Medgold, said: "We are pleased to close our financing with Fortuna Silver Mines, and speaking on behalf of the Medgold team, we're all looking forward to starting work with them in Serbia under our strategic alliance. Our early stage work has identified a number of key district-scale targets which are the focus of our first licence applications there. We hope to have the first licences issued in the late summer or early fall of this year. Our experienced team of geologists is planning a busy summer field season of reconnaissance and target generation work, and we'll be starting more detailed work on the targets we've already identified." About Medgold Medgold is a European-focused, TSX-V listed exploration and development company targeting gold properties in northwest Iberia and the under-explored gold provinces of southern Europe. Run by a highly experienced management team with a successful track record of building value in resource companies, Medgold is aiming to become a leading European gold company. Additional information on Medgold can be found on the Company's website at www.medgoldresources.com and by reviewing the Company's page on SEDAR at www.sedar.com. ON BEHALF OF THE BOARD Simon Ridgway, Chief Executive Officer Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. Forward-looking statements Certain statements contained in this news release constitute forward-looking statements within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, are forward-looking statements and include, without limitation, statements about the intended use of the financing proceeds. Often, but not always, these forward looking statements can be identified by the use of words such as "estimate", "estimates", "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "upgraded", "offset", "limited", "contained", "reflecting", "containing", "remaining", "to be", "periodically", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by forward-looking statements. Such uncertainties and factors include, among others, whether the Company will spend the financing proceeds as intended; changes in general economic conditions and financial markets; the Company or any joint venture partner not having the financial ability to meet its exploration and development goals; risks associated with the results of exploration and development activities, estimation of mineral resources and the geology, grade and continuity of mineral deposits; unanticipated costs and expenses; and such other risks detailed from time to time in the Company's quarterly and annual filings with securities regulators and available under the Company's profile on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to: that the Company will spend the financing proceeds as intended; that the Company's stated goals and planned exploration and development activities will be achieved; that there will be no material adverse change affecting the Company or its properties; and such other assumptions as set out herein. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on forward-looking statements.





Medgold Resources Corp.
Dan James (UK)
President
44 7972 579188
[email protected]
Medgold Resources Corp.
Ralph Rushton (Vancouver)
Investor Relations
1 604-630-5544
[email protected]
www.medgoldresources.com




Read more...
Medgold Secures $1.5-million Investment and Strategic Alliance for Serbian Exploration

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 13, 2016) - Medgold Resources Corp. (TSX VENTURE:MED) (the "Company" or "Medgold") is pleased to announce a C$1.5-million strategic investment in the Company by Fortuna Silver Mines Inc. ("Fortuna"), a leading mid-tier precious metals miner. The private placement is part of a broader strategic alliance between Medgold and Fortuna to explore for precious metal deposits in Serbia. Subject to stock exchange approval, Fortuna will purchase 10.0 million units at $0.15 per unit, representing a premium of 36% to the closing price of Medgold's shares on June 10. Each unit is comprised of one common share in Medgold and one warrant entitling Fortuna to acquire one additional Medgold common share at $0.15 for a period of 12 months. Medgold will use the proceeds of the private placement on project-generating exploration in Serbia within 12 months. If Fortuna exercises its warrants, Medgold will use the exercise proceeds on further exploration work in Serbia within 12 months following the date of the warrant exercise. In conjunction with the private placement, Medgold has granted Fortuna the right to enter into an option agreement to earn up to a 70% interest in one of the geological target areas (a "Selected Property") identified by Medgold's project generation and exploration work in Serbia, by spending a total of US$8.0 million on the Selected Property and completing a PEA. Dan James, the President of Medgold, said: "I'm delighted to welcome Fortuna as a strategic investor into Medgold. Our early-stage work in Serbia is already generating some very interesting targets - we have eight licences currently under application with the Ministry of Mines. Our agreement with Fortuna firstly secures the funding we need -at a premium to market- to kick off an aggressive project generation program in the country. Secondly, it provides Medgold with a potential partner for the advanced exploration to possible PEA level of at least one of the targets generated by our work. Once we make a discovery, we can tap into the experience of Fortuna's first-rate mining, engineering and geological team who have re-commissioned the Caylloma mine in Peru, and built and operate a modern underground silver-gold mine at San Jose in Mexico, which is acknowledged as one of the best run silver mines in the industry. Fortuna's geological team has already spent time on the ground with our geologists reviewing some early-stage targets and we're excited to start working with them as we move our strategic alliance forward." Option Terms To acquire an initial 51% interest in the Selected Property, Fortuna must spend a minimum of US$3.0 million on the Selected Property by no later than the third anniversary of the date of the option agreement. Once it has earned 51% Fortuna can elect to form a 51:49 joint venture with Medgold to further develop the Selected Property; or Fortuna can elect to be granted the option to earn an additional 19% interest in the Selected Property by completing a Preliminary Economic Assessment on the Property and spending an additional US$5.0 million in qualified expenditures within three years following the date of the election by Fortuna. About Fortuna Silver Mines Inc.
Fortuna is a growth oriented, silver and base metal producer focused on mining opportunities in Latin America. Its primary assets are the Caylloma silver mine in southern Peru and the San Jose silver-gold mine in Mexico. The company is selectively pursuing acquisition opportunities throughout the Americas and in select other areas. For more information, please visit its website at www.fortunasilver.com. About Medgold Medgold is a European-focused, TSX-V listed exploration and development company targeting gold properties in northwest Iberia and the under-explored gold provinces of southern Europe. Run by a highly experienced management team with a successful track record of building value in resource companies, Medgold is aiming to become a leading European gold company. Additional information on Medgold can be found on the Company's website at www.medgoldresources.com and by reviewing the Company's page on SEDAR at www.sedar.com. ON BEHALF OF THE BOARD Daniel P. James, President & Director Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. Forward-looking statements Certain statements contained in this news release constitute forward-looking statements within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, are forward-looking statements and include, without limitation, statements about the proposed strategic alliance between the Company and Fortuna. Often, but not always, these forward looking statements can be identified by the use of words such as "estimate", "estimates", "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "upgraded", "offset", "limited", "contained", "reflecting", "containing", "remaining", "to be", "periodically", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by forward-looking statements. Such uncertainties and factors include, among others, completion of the private placement; advancement of the strategic alliance between the Company and Fortuna; changes in general economic conditions and financial markets; the Company or any joint venture partner not having the financial ability to meet its exploration and development goals; risks associated with the results of exploration and development activities, estimation of mineral resources and the geology, grade and continuity of mineral deposits; unanticipated costs and expenses; and such other risks detailed from time to time in the Company's quarterly and annual filings with securities regulators and available under the Company's profile on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to: that the private placement will be completed as planned; that the strategic alliance between the Company and Fortuna will advance as anticipated; that the Company's stated goals and planned exploration and development activities will be achieved; that there will be no material adverse change affecting the Company or its properties; and such other assumptions as set out herein. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on forward-looking statements.





Medgold Resources Corp.
President
Dan James (UK)
[email protected]
44 7972 579188
Medgold Resources Corp.
Investor Relations
Ralph Rushton (Vancouver)
[email protected]
1 604-630-5544




Read more...
Director Boosts Stake in Sears as Retail Companies Become Hot Buys Retail stocks demonstrate high performance and profitability
On June 1, Bruce Berkowitz (Trades, Portfolio) of Fairholme Capital Management increased his Sears Holding Group (NASDAQ:SHLD) holding by 2.78%, buying the additional shares at an average price of $12.50 per share. The fund also made a $10.13 billion insider transaction, buying 778,000 shares of Sears’ stock at an average price of $13.02 per share. Read more...
Medgold Completes Private Placement

VANCOUVER, CANADA--(Marketwired - May 16, 2016) - Medgold Resources Corp. (TSX VENTURE:MED) (the "Company" or "Medgold") is pleased to advise that it has closed its previously announced non-brokered private placement financing with the issuance of 2.0 million units at $0.10 per unit, for proceeds of $200,000. Each unit consists of one common share and one warrant entitling the holder to purchase one additional common share of the Company at $0.12 for one year from closing. The common shares and warrants issued are subject to a resale restriction until September 11, 2016. No finder's fees or commissions were paid in connection with this financing. The proceeds of the placement will be used to fund the ongoing exploration of the Company's properties, and for general working capital purposes. About Medgold Medgold is a European-focused, TSX-V listed exploration and development company targeting gold properties in northwest Iberia and the under-explored gold provinces of southern Europe. Run by a highly experienced management team with a successful track record of building value in resource companies, Medgold is aiming to become a leading European gold company. Additional information on Medgold can be found on the Company's website at www.medgoldresources.com and by reviewing the Company's page on SEDAR at www.sedar.com. ON BEHALF OF THE BOARD "Dan James" Daniel P. James, President & Director Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. Forward-looking statements Certain statements contained in this news release constitute forward-looking statements within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, are forward-looking statements and include, without limitation, statements about the intended use of the financing proceeds. Often, but not always, these forward looking statements can be identified by the use of words such as "estimate", "estimates", "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "upgraded", "offset", "limited", "contained", "reflecting", "containing", "remaining", "to be", "periodically", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by forward-looking statements. Such uncertainties and factors include, among others, whether the Company will spend the financing proceeds as intended; changes in general economic conditions and financial markets; the Company or any joint venture partner not having the financial ability to meet its exploration and development goals; risks associated with the results of exploration and development activities, estimation of mineral resources and the geology, grade and continuity of mineral deposits; unanticipated costs and expenses; and such other risks detailed from time to time in the Company's quarterly and annual filings with securities regulators and available under the Company's profile on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to: that the Company will spend the financing proceeds as intended; that the Company's stated goals and planned exploration and development activities will be achieved; that there will be no material adverse change affecting the Company or its properties; and such other assumptions as set out herein. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on forward-looking statements.





Medgold Resources Corp.
President
Dan James (UK)
[email protected]
44 7972 579188
Medgold Resources Corp.
Investor Relations
Ralph Rushton (Vancouver)
[email protected]
1 604-630-5544




Read more...

Ratios

vs
industry
vs
history
PE Ratio 29.73
MED's PE Ratio is ranked lower than
69% of the 689 Companies
in the Global Specialty Retail industry.

( Industry Median: 21.22 vs. MED: 29.73 )
Ranked among companies with meaningful PE Ratio only.
MED' s PE Ratio Range Over the Past 10 Years
Min: 8.97  Med: 20.75 Max: 56.26
Current: 29.73
8.97
56.26
PE Ratio without NRI 29.73
MED's PE Ratio without NRI is ranked lower than
69% of the 679 Companies
in the Global Specialty Retail industry.

( Industry Median: 20.85 vs. MED: 29.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
MED' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.97  Med: 19.32 Max: 56.26
Current: 29.73
8.97
56.26
Price-to-Owner-Earnings 52.53
MED's Price-to-Owner-Earnings is ranked lower than
85% of the 429 Companies
in the Global Specialty Retail industry.

( Industry Median: 18.91 vs. MED: 52.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MED' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.6  Med: 21.16 Max: 234.55
Current: 52.53
7.6
234.55
PB Ratio 5.51
MED's PB Ratio is ranked lower than
86% of the 908 Companies
in the Global Specialty Retail industry.

( Industry Median: 1.71 vs. MED: 5.51 )
Ranked among companies with meaningful PB Ratio only.
MED' s PB Ratio Range Over the Past 10 Years
Min: 1.36  Med: 4.02 Max: 10.55
Current: 5.51
1.36
10.55
PS Ratio 1.94
MED's PS Ratio is ranked lower than
78% of the 906 Companies
in the Global Specialty Retail industry.

( Industry Median: 0.68 vs. MED: 1.94 )
Ranked among companies with meaningful PS Ratio only.
MED' s PS Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.27 Max: 4.34
Current: 1.94
0.49
4.34
Price-to-Free-Cash-Flow 23.64
MED's Price-to-Free-Cash-Flow is ranked lower than
62% of the 403 Companies
in the Global Specialty Retail industry.

( Industry Median: 17.41 vs. MED: 23.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MED' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.42  Med: 16.29 Max: 139.65
Current: 23.64
8.42
139.65
Price-to-Operating-Cash-Flow 20.96
MED's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 496 Companies
in the Global Specialty Retail industry.

( Industry Median: 11.04 vs. MED: 20.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MED' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.44  Med: 12.43 Max: 51.95
Current: 20.96
5.44
51.95
EV-to-EBIT 16.86
MED's EV-to-EBIT is ranked lower than
58% of the 1045 Companies
in the Global Specialty Retail industry.

( Industry Median: 14.87 vs. MED: 16.86 )
Ranked among companies with meaningful EV-to-EBIT only.
MED' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.8  Med: 11.5 Max: 35.6
Current: 16.86
4.8
35.6
EV-to-EBITDA 14.04
MED's EV-to-EBITDA is ranked lower than
62% of the 1089 Companies
in the Global Specialty Retail industry.

( Industry Median: 11.23 vs. MED: 14.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
MED' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.9  Med: 8.6 Max: 28.4
Current: 14.04
3.9
28.4
PEG Ratio 14.14
MED's PEG Ratio is ranked lower than
91% of the 300 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.25 vs. MED: 14.14 )
Ranked among companies with meaningful PEG Ratio only.
MED' s PEG Ratio Range Over the Past 10 Years
Min: 0.22  Med: 0.8 Max: 9.55
Current: 14.14
0.22
9.55
Shiller PE Ratio 37.76
MED's Shiller PE Ratio is ranked lower than
74% of the 243 Companies
in the Global Specialty Retail industry.

( Industry Median: 20.72 vs. MED: 37.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
MED' s Shiller PE Ratio Range Over the Past 10 Years
Min: 22.05  Med: 34.86 Max: 106.67
Current: 37.76
22.05
106.67
Current Ratio 4.15
MED's Current Ratio is ranked higher than
91% of the 876 Companies
in the Global Specialty Retail industry.

( Industry Median: 1.58 vs. MED: 4.15 )
Ranked among companies with meaningful Current Ratio only.
MED' s Current Ratio Range Over the Past 10 Years
Min: 0.58  Med: 3.08 Max: 5.62
Current: 4.15
0.58
5.62
Quick Ratio 3.40
MED's Quick Ratio is ranked higher than
93% of the 875 Companies
in the Global Specialty Retail industry.

( Industry Median: 0.85 vs. MED: 3.40 )
Ranked among companies with meaningful Quick Ratio only.
MED' s Quick Ratio Range Over the Past 10 Years
Min: 0.27  Med: 2.17 Max: 3.8
Current: 3.4
0.27
3.8
Days Inventory 75.54
MED's Days Inventory is ranked higher than
57% of the 868 Companies
in the Global Specialty Retail industry.

( Industry Median: 89.83 vs. MED: 75.54 )
Ranked among companies with meaningful Days Inventory only.
MED' s Days Inventory Range Over the Past 10 Years
Min: 74.24  Med: 85.1 Max: 165.97
Current: 75.54
74.24
165.97
Days Sales Outstanding 1.84
MED's Days Sales Outstanding is ranked higher than
88% of the 696 Companies
in the Global Specialty Retail industry.

( Industry Median: 13.59 vs. MED: 1.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
MED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.88  Med: 1.83 Max: 2.2
Current: 1.84
0.88
2.2
Days Payable 50.77
MED's Days Payable is ranked lower than
53% of the 657 Companies
in the Global Specialty Retail industry.

( Industry Median: 53.24 vs. MED: 50.77 )
Ranked among companies with meaningful Days Payable only.
MED' s Days Payable Range Over the Past 10 Years
Min: 44.99  Med: 57.54 Max: 66.79
Current: 50.77
44.99
66.79

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.56
MED's Dividend Yield % is ranked higher than
56% of the 974 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.31 vs. MED: 2.56 )
Ranked among companies with meaningful Dividend Yield % only.
MED' s Dividend Yield % Range Over the Past 10 Years
Min: 0.81  Med: 2.28 Max: 2.77
Current: 2.56
0.81
2.77
Dividend Payout Ratio 0.72
MED's Dividend Payout Ratio is ranked lower than
73% of the 557 Companies
in the Global Specialty Retail industry.

( Industry Median: 0.49 vs. MED: 0.72 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MED' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.15  Med: 0.44 Max: 0.72
Current: 0.72
0.15
0.72
Forward Dividend Yield % 2.87
MED's Forward Dividend Yield % is ranked higher than
59% of the 936 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.42 vs. MED: 2.87 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.55
MED's 5-Year Yield-on-Cost % is ranked lower than
54% of the 1183 Companies
in the Global Specialty Retail industry.

( Industry Median: 2.69 vs. MED: 2.55 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MED' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.81  Med: 2.28 Max: 2.77
Current: 2.55
0.81
2.77
3-Year Average Share Buyback Ratio 3.30
MED's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 495 Companies
in the Global Specialty Retail industry.

( Industry Median: -0.40 vs. MED: 3.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MED' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4  Med: -6.05 Max: 8
Current: 3.3
-20.4
8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.25
MED's Price-to-Net-Cash is ranked higher than
54% of the 109 Companies
in the Global Specialty Retail industry.

( Industry Median: 12.34 vs. MED: 10.25 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MED' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 9.07  Med: 20.67 Max: 145.62
Current: 10.25
9.07
145.62
Price-to-Net-Current-Asset-Value 6.95
MED's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 435 Companies
in the Global Specialty Retail industry.

( Industry Median: 4.55 vs. MED: 6.95 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MED' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.94  Med: 11.15 Max: 35.25
Current: 6.95
5.94
35.25
Price-to-Tangible-Book 5.51
MED's Price-to-Tangible-Book is ranked lower than
81% of the 827 Companies
in the Global Specialty Retail industry.

( Industry Median: 1.97 vs. MED: 5.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MED' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.27  Med: 4.04 Max: 12.33
Current: 5.51
1.27
12.33
Price-to-Intrinsic-Value-Projected-FCF 1.71
MED's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
65% of the 453 Companies
in the Global Specialty Retail industry.

( Industry Median: 1.24 vs. MED: 1.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MED' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.03  Med: 3.24 Max: 11.22
Current: 1.71
1.03
11.22
Price-to-Median-PS-Value 1.52
MED's Price-to-Median-PS-Value is ranked lower than
77% of the 729 Companies
in the Global Specialty Retail industry.

( Industry Median: 1.04 vs. MED: 1.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MED' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 1.06 Max: 4.83
Current: 1.52
0.13
4.83
Price-to-Graham-Number 2.71
MED's Price-to-Graham-Number is ranked lower than
73% of the 561 Companies
in the Global Specialty Retail industry.

( Industry Median: 1.50 vs. MED: 2.71 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MED' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.31  Med: 1.94 Max: 5.92
Current: 2.71
0.31
5.92
Earnings Yield (Greenblatt) % 5.93
MED's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 1260 Companies
in the Global Specialty Retail industry.

( Industry Median: 5.60 vs. MED: 5.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MED' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 8.7 Max: 20.7
Current: 5.93
2.8
20.7
Forward Rate of Return (Yacktman) % 7.31
MED's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 539 Companies
in the Global Specialty Retail industry.

( Industry Median: 4.62 vs. MED: 7.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MED' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.2  Med: 26.7 Max: 47.8
Current: 7.31
7.2
47.8

More Statistics

Revenue (TTM) (Mil) $274.5
EPS (TTM) $ 1.50
Beta0.51
Short Percentage of Float6.65%
52-Week Range $29.84 - 46.36
Shares Outstanding (Mil)11.92
» More Articles for MED

Headlines

Articles On GuruFocus.com
Medgold Is Granted a Drilling Permit at the Boticas Gold Project, Portugal Jul 06 2016 
Piotroski F-Score Study: Specialty Retail Companies Offer Hot Buys Jul 06 2016 
Medgold Grants Stock Options Jun 29 2016 
Medgold Completes Private Placement to Fortuna Silver Mines Jun 21 2016 
Medgold Secures $1.5-million Investment and Strategic Alliance for Serbian Exploration Jun 13 2016 
Insiders Roundup: Buys of Advance Auto Parts, Sales of Fitbit Jun 03 2016 
Director Boosts Stake in Sears as Retail Companies Become Hot Buys Jun 02 2016 
Medgold Completes Private Placement May 16 2016 
Guru Stocks With Strong 10-Year Returns May 12 2016 
Medgold Continues to Expand the Boticas Gold Project, Portugal; Proposes $200,000 Private Placement Apr 11 2016 

More From Other Websites
Medifast, Inc. – Value Analysis (NYSE:MED) : April 19, 2017 Apr 19 2017
Medifast, Inc. breached its 50 day moving average in a Bullish Manner : MED-US : April 18, 2017 Apr 18 2017
Medifast CEO receives nearly $3 million in 2016 Apr 10 2017
Top Ranked Income Stocks to Buy for April 5th Apr 05 2017
Medifast, Inc. breached its 50 day moving average in a Bearish Manner : MED-US : April 5, 2017 Apr 05 2017
Medifast, Inc. breached its 50 day moving average in a Bullish Manner : MED-US : March 23, 2017 Mar 23 2017
Medifast, Inc. : MED-US: Dividend Analysis : March 23rd, 2017 (record date) : By the numbers : March... Mar 22 2017
Medifast, Inc. :MED-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Edited Transcript of MED earnings conference call or presentation 9-Mar-17 9:30pm GMT Mar 09 2017
Medifast posts 4Q profit Mar 09 2017
Medifast, Inc. Announces Fourth Quarter and Full Year 2016 Financial Results Mar 09 2017
10 Best Performing Weight Loss Companies And Their Programs Mar 09 2017
Medifast, Inc. Announces Quarterly Dividend Mar 07 2017
Medifast, Inc. to Announce Financial Results for the Fourth Quarter and Fiscal Year Ended December... Feb 23 2017
Take Shape For Life® Hosts Largest Go Global Leadership Conference Ever Feb 20 2017
Medifast, Inc. – Value Analysis (NYSE:MED) : January 18, 2017 Jan 18 2017
ETFs with exposure to Medifast, Inc. : January 17, 2017 Jan 17 2017
Medifast, Inc. breached its 50 day moving average in a Bearish Manner : MED-US : January 13, 2017 Jan 13 2017
Medifast, Inc. to Participate in the 19th Annual ICR Conference Jan 03 2017
Year in Review 2016: How Baltimore area public companies fared in 2016 Dec 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)